IKİrFan Kuku

İrFan Kuku

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


İrFan Kuku has a total of 74 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Early Bacterial Bloodstream Infection After Allogeneic Hematopoietic Stem Cell Transplantation: Incidence, Microbiology and Outcomes in a Single Turkish Center

    by Ahmet Sarıcı, Emin Kaya, İrfan Kuku, Mehmet Ali Erkurt, İlhami Berber, Elif Seren Tanrıverdi, Funda Memişoğlu, Shahin Javanmard, Mustafa Buğrahan Berktaş, Soykan Biçim, et al.

    Background/Objectives: Bloodstream infections (BSIs) are a major complication of allogeneic hematopoietic stem cell transplantation (allo-HSCT), and reported incidence depends on how skin commensals are adjudicated. We describe the epidemiology, microbiology, risk factors, and survival impact of early (day 0–30) bacterial BSI at a Turkish transplant center. Methods: We retrospectively studied 155 consecutive allo-HSCT episodes in 153 adults (April 2017–January 2026). Single-isolate coagulase-negative staphylococci (CoNS) were classified as contaminants. Cumulative incidence was estimated with the Aalen–Johansen estimator and survival with day-30 landmark and time-dependent Cox models. Results: Bacterial BSI occurred in 20 episodes (30-day cumulative incidence 12.9%, 95% CI 8.2–18.7) at a median of 14 days; counting single-isolate CoNS would have raised incidence to 40.0%. Of 22 isolates, 15 (68.2%) were Gram-negative and 12 (54.5%) were Escherichia coli. An extended-spectrum β-lactamase phenotype was present in nine episodes. Among 14 Gram-negative episodes with susceptibility data, 71.4% were fluoroquinolone-resistant and 92.9% meropenem-susceptible; empirical therapy was active in 16 of 20 episodes (80.0%). No baseline covariate predicted BSI, and early BSI was not associated with overall survival (adjusted HR 0.75, 95% CI 0.34–1.64). Conclusions: Early bacterial BSI was predominantly Gram-negative and E. coli-driven, with frequent fluoroquinolone resistance but preserved carbapenem susceptibility. Contaminant adjudication substantially altered incidence and should be stated explicitly.

  • Open Access

    Documented Infections and Mortality in Patients Receiving Bruton Tyrosine Kinase Inhibitors: A Single-Center Retrospective Cohort of B-Cell Malignancies and Chronic Graft-Versus-Host Disease

    by Ahmet Sarıcı, Emin Kaya, İrfan Kuku, Mehmet Ali Erkurt, İlhami Berber, Shahin Javanmard, Funda Memişoğlu, Elif Seren Tanrıverdi, Mustafa Buğrahan Berktaş, Barış Otlu

    Background/Objectives: Infection burden during Bruton tyrosine kinase inhibitor (BTKi) treatment is difficult to interpret when infection onset, treatment initiation, and discontinuation are incompletely documented. We described the timing, microbiology, and mortality of documented infections and explored the association between peri-initiation albumin and documented infection. Methods: This retrospective single-center cohort included 76 patients treated with ibrutinib or acalabrutinib for B-cell malignancies or chronic graft-versus-host disease (cGVHD). The first documented on-treatment infection was analyzed using Aalen–Johansen cumulative incidence, with death or permanent treatment discontinuation as competing events. Sensitivity analyses included a day-30 landmark analysis, a total-burden analysis that also counted infections after discontinuation, and indication-specific estimates. Albumin associations were assessed through day 90, with Benjamini–Hochberg correction across seven exploratory comparisons. Results: Fifty-eight patients had B-cell malignancies and 18 had cGVHD; median follow-up by reverse Kaplan–Meier was 244 days. A qualifying infection occurred in 27/76 patients (35.5%); 17/27 were recorded within 30 days, of which one was suggestive of pre-existing infection and 16 were indeterminate. The cumulative incidence at day 180 was 30.5% (95% CI 19.9–41.5%) on treatment and 38.1% (95% CI 26.2–50.4%) when post-discontinuation infections were included. Among 49 patients still eligible at day 30, the conditional incidence by original day 180 was 11.2% (95% CI 2.4–21.3%). Respiratory and urinary foci accounted for 13/27 and 9/27 infections, respectively. Twenty-nine patients (38.2%) died; 17/29 deaths were recorded as infection-related. Median albumin was lower in patients with infection by day 90 (3.05 versus 3.80 g/dL; nominal p = 0.009), but this exploratory difference did not meet the multiplicity-adjusted threshold (q = 0.065) and attenuated when first-week infections were excluded. Conclusions: Documented infections and infection-related deaths were frequent in this heterogeneous cohort, but uncertain onset limits the interpretation of the early cluster. The albumin finding is hypothesis-generating and does not establish prediction or causation.

  • Open Access

    Blood Culture-Based Classification of Early Bacterial Bloodstream Infection After Autologous Hematopoietic Stem Cell Transplantation: A Retrospective Cohort Study

    by Ahmet Sarıcı, Emin Kaya, İrfan Kuku, Mehmet Ali Erkurt, İlhami Berber, Elif Seren Tanrıverdi, Funda Memisoglu, Shahin Javanmard, Mustafa Bugrahan Berktas, Baris Otlu

    Estimates of early bacterial bloodstream infection (BSI) after autologous hematopoietic stem cell transplantation (HSCT) depend on the classification of common commensals. We examined the sensitivity of BSI frequency and microbiology to three operational definitions. This retrospective single-center cohort comprised 161 autologous transplant episodes in 158 patients from September 2015 to February 2026. The endpoint covered day 0–30. A permissive rule counted any bacterial growth. The primary definition excluded CoNS-only episodes classified as contamination following retrospective review of blood culture results and clinical records. A restrictive definition additionally excluded episodes with sole viridans-group or unspeciated streptococci or Corynebacterium. Formal adjudication according to the full National Healthcare Safety Network surveillance criteria was not performed. Regression and survival analyses were exploratory. The proportions meeting the permissive, primary, and restrictive endpoints were 56.5% (91/161), 23.6% (38/161; 95% confidence interval 17.3–30.9), and 21.1% (34/161), respectively. The primary definition included 40 isolates, of which 27 (67.5%) were Gram-negative and 21 (52.5%) were Escherichia coli. Gram-positive isolates predominated under the permissive rule (71.0%). Exploratory regression estimates were imprecise. In the day-30 landmark survival analysis, the operational BSI classification was inversely associated with subsequent mortality; however, this finding was based on only four deaths in the BSI-classified group and remained vulnerable to survivor selection, residual confounding, and exposure misclassification. Reported BSI frequency and organism distribution were sensitive to commensal classification. Explicit operational definitions, retrospective clinical assessment of CoNS isolates, and sensitivity analyses aid interpretation; however, the absence of standardized surveillance adjudication limits the estimation of true BSI incidence. The survival findings require cautious, noncausal interpretation.


  • CD34+ cell dose as a determinant of engraftment kinetics after autologous stem cell transplantation in lymphoma

    by Ahmet Sarıcı, Mehmet Ali Erkurt, İrFan Kuku, Emin Kaya, İlHami Berber, Soykan Biçim, Emine Hidayet, Ahmet Kaya, Aşkı Vural, Onur Selçuk Yiğit, et al.

    Aims: Lymphomas are heterogeneous hematologic malignancies for which autologous hematopoietic stem cell transplantation (ASCT) remains an important therapeutic option in relapsed or refractory disease. In addition to patient- and disease-related factors, graft-related parameters—particularly the infused CD34+ cell dose—play a critical role in hematopoietic recovery after ASCT. This study aimed to evaluate post-transplant engraftment and long-term survival outcomes in patients with Hodgkin and non-Hodgkin lymphoma according to infused CD34+ cell dose. Methods: Demographic characteristics, primary diagnosis, infused CD34+ cell dose, neutrophil and platelet engraftment times, 1-year mortality, and 5-year survival were retrospectively obtained from hospital electronic records. Patients were stratified into two groups based on infused CD34+ cell dose: 2–5 × 106/kg and >5 × 106/kg. Engraftment times and survival outcomes were compared between groups. Results: A total of 165 patients were included (2–5 × 106/kg, n = 67; >5 × 106/kg, n = 98). Baseline characteristics, including age, sex, and lymphoma subtype, were comparable between groups. Neutrophil and platelet engraftment times were significantly longer in the 2–5 × 106/kg group than in the >5 × 106/kg group (p < 0.001 for both). In the overall cohort, CD34+ cell dose was negatively correlated with engraftment times. However, no significant differences were observed in 1-year mortality or 5-year survival between groups. Conclusion: Adequate CD34+ cell dosing is essential for rapid hematopoietic recovery after ASCT, whereas higher doses do not appear to confer additional long-term survival benefit.

  • Open Access

    Real-World Outcomes of Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia

    by Asli Odabasi Giden, Duzgun Ozatli, Mehmet Ali Erkurt, Abdullah Karakus, Gulden Sincan, Fehmi Hindilerden, Yusuf Bilen, Ugur Hatipoglu, Gulsum Akgun Cagliyan, Tuba Hacibekiroglu, et al.

    Background: Chronic lymphocytic leukemia (CLL) is a biologically heterogeneous disease characterized by variable clinical outcomes. The introduction of targeted therapies, particularly the BCL-2 inhibitor venetoclax, has significantly improved treatment outcomes in patients with relapsed/refractory (R/R) CLL. However, real-world data on the safety and effectiveness of venetoclax-based regimens remain limited. Methods: In this multicenter retrospective study, 147 adult patients with R/R CLL treated with venetoclax between April 2019 and August 2025 were analyzed. Venetoclax was administered as monotherapy or in combination with rituximab, obinutuzumab, or ibrutinib. Adverse events were graded according to CTCAE v4.0, and treatment responses were assessed based on IWCLL criteria. Survival outcomes, including overall survival (OS) and progression-free survival (PFS), were evaluated using Kaplan–Meier analysis. Results: The median age at venetoclax initiation was 64 years, and patients had received a median of two prior lines of therapy. Combination therapy was administered in 78.9% of patients. The overall response rate was 83.0%, including complete remission in 65.3% of patients. Grade ≥ 3 hematologic adverse events included neutropenia (18.4%), thrombocytopenia (14.3%), and anemia (7.5%). Tumor lysis syndrome (TLS) occurred in 28.6% of patients, predominantly during the dose ramp-up phase. At a median follow-up of 61 months, median OS and PFS were both 60 months. Bulky disease was associated with inferior survival outcomes. Conclusions: Venetoclax-based therapy is effective and well tolerated in patients with R/R CLL in a real-world setting. High response rates and durable survival outcomes were observed despite the inclusion of patients with high-risk clinical and biological features. These findings support the use of venetoclax as a key component of modern CLL treatment strategies and highlight the importance of real-world evidence in optimizing patient management.

  • Impact of pretransplant CONUT score on posttransplant engraftment kinetics and overall survival in patients with multiple myeloma

    by Süleyman Arslan, Mehmet Ali Erkurt, İrFan Kuku, Emin Kaya, İlHami Berber, Ahmet Sarıcı, Ahmet Kaya

  • Cytomegalovirus Infection Risk Factors in Allogeneic Hematopoietic Stem Cell Transplantation Can Defibrotide Be a Risk Factor?

    by Lecturer Zeynep Burçin Yılmaz, Funda Memişoğlu, Emine Hidayet, İrFan Kuku, Mehmet Ali Erkurt, Emin Kaya, İlHami Berber

  • Open Access

    Etiologic evaluation of male patients diagnosed with anemia in the first consultation of the hematology department

    by Arzu Uzun, İrFan Kuku, Emin Kaya, Mehmet Ali Erkurt

    Aims: Anemia is a decrease in hemoglobin (Hb) levels below the normal values determined by gender. Since anemia is a laboratory finding, its etiology must be investigated. The present study aimed to investigate the etiologic spectrum of male patients diagnosed with anemia in the first consultation of a tertiary hospital hematology department. Methods: This study was conducted with male patients who were consulted at İnönü University, Turgut Özal Medical Center, adult hematology department between the dates of 2010-2015. Adult male patients aged 18 years and older, who were diagnosed with anemia in the first consultation were included in the study. Hb levels under 13 g/dl in the complete blood count were accepted as anemia criteria. The study was carried out retrospectively by examining the records of the hospital automation system. Results: The records of a total number of 7840 adult male patients were examined and 473 (6%) of them were found to have anemia when they first consulted in the hematology department. Iron deficiency was the most common etiological cause with the number of 97 patients (20.5%). In the first consultation; malign diseases were found in 50.3% (238), and benign diseases were found in 49.7% (235) of the patients, as the etiologic causes of the anemia. Multiple myeloma (MM) was found to be the most common malignant disease with a rate of 26.5% (63 patients), and isolated iron deficiency was found to be the most common benign disease with a rate of 41.3 % (97 patients); among the etiologic factors or anemia. Conclusion: In our study, malignant diseases were detected as the etiological cause in more than half of the adult male patients with anemia in their first consultation. We think that it is important to keep this situation in mind in the etiology of anemias, especially considering the profile of patients referred to tertiary hospitals.

  • Effects of extracorporeal photopheresis on survival in chronic graft versus host disease

    by Ahmet Kaya, Mehmet Ali Erkurt, İrFan Kuku, Emin Kaya, İlHami Berber, Soykan Biçim, Süleyman Arslan, Ayse Uysal, Fatma Hilal Yagın

    Objective: Chronic graft versus host disease (cGVHD) develops after allogeneic hematopoietic cell transplantation, when immune cells from a non-identical donor initiate an immune reaction against the transplant recipient. Extracorporeal photopheresis (ECP) can be used in combination with prednisone in steroid-resistant cGVHD. In this study, the effect of ECP use on survival in cGVHD was examined. Patients and Methods: Twenty-six patients who were followed up in the adult Hematology Clinic of Inonu University Turgut Ozal Medical Center for cGVHD were included in the study. Stem cell transplantation and ECP application parameters that may affect the survival of the patients were examined. Results: The degree of involvement in cGVHD affects survival. Involvements with clinical and laboratory scores of 2 and above according to the National Institutes of Health consensus criteria, significantly reduced survival. The development time of cGVHD was found to be associated with survival, and that it had a positive impact on survival, especially when the disease developed after 220 days after the transplantation. It was observed that steroid dose taken during ECP, patient age and cGVHD prophylaxis used affected survival. Conclusion: The use of ECP may be effective in survival, especially, in patients who develop cGVHD, 220 days after allogeneic transplantation. Concurrent use of steroids with ECP affects survival.


  • Open Access

    The role of therapeutic plasma exchange in the treatment of patients with septic shock- single center experience

    by Selahattin Çelik, Mehmet Ali Erkurt, Ahmet Sarıcı, İrfan Kuku, Emin Kaya, İlhami Berber, Samet Yıldız

    Aims: Sepsis is a life-threatening organ dysfunction resulting from an excessive inflammatory response in the host due to infection. Due to the activation of the coagulation system in sepsis, the search for treatment has shifted in this direction and therapeutic plasma exchange (TPE). This study, it was aimed to compare the hemogram and biochemical values and inflammatory markers of patients who underwent TPE before and after TPE. Methods: The research data were obtained retrospectively from the records on the hospital system of the patients who were hospitalized in Malatya İnönü University Faculty of Medicine Intensive Care Clinic and were treated with TPE. Results: A total of 25 patients were included. It was observed that platelet count (p=0.427), hemoglobulin (p=0.545), leukocyte (p=0.527) and neutrophil (p=0.657) counts decreased statistically after TPE. It was observed that C-reactive protein (p=0.065) and procalcitonin (p=0.267) values also decreased after TPE procedure. Among the direct bilirubin (p=0.326), total bilirubin (p=0.397), AST (p=0.840) and alanine transferase(ALT) (p=0.122) values, it was determined that the aspartate transferase (AST) value increased after the TPE procedure and the others decreased. It was observed that the blood urea nitrogen (p=0.326) value increased after TPE procedure, while creatinine (p=0.677) value decreased. Conclusion: TPE process can reduce harmful components in plasma. Since it is of vital importance to reduce harmful components in the plasma in sepsis, TPE can be applied by evaluating patient-specifically. Our study is important in terms of showing that TPE can be an alternative treatment modality in patients with sepsis and septic shock.